Search Results 921-930 of 16350 for monoclonal antibody

1. Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma - Mayo Clinic

   Monoclonal antibody; at least three half-lives since the last dose; Non-antibody immunotherapy (e.g., tumor vaccine); at least 42 days since last dose ...

2. Clinical Trials - Mayo Nephrology Collaborative Group

   Assess the effectiveness of daratumumab SC in treating patients with monoclonal immunoglobulin deposits (PGNMID) by assessing improvement in proteinuria at 12 ...

3. Model Clarifies Immunotherapy for Multiple Myeloma - Mayo Clinic News Network

   Bispecific-T-cell-engaged-antibodies immunotherapy is similar to a treatment where the patient's T cells are collected, genetically altered to "see" their ...

4. Stereotactic Radiosurgery Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a ...

5. A Study Comparing CAR-T Therapy Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants with Relapsed and Lenalidomide-Refractory Multiple Myeloma - Mayo Clinic

   Serum monoclonal paraprotein (M-protein) level ≥ 1.0 gram per deciliter ... Monoclonal antibody treatment within 21 days. Cytotoxic therapy within 14 ...

6. A Study of Cell, Serum, and Bone Marrow Bank for Patients receiving Chimeric Antigen Receptor T Cell Therapy for the Treatment of Cancer - Mayo Clinic

   ... antibodies and the factors that may determine disease progression and treatment response. ... Plan to initiate treatment with either bi-specific antibody or CAR-T ...

7. Mayo researchers identify biomarker to speed diagnosis in brain and spinal cord inflammation

   Antibodies are molecules used by the immune system to fight infections or cancer. When an antibody is directed against healthy tissue by a misguided immune ...

8. Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer - Mayo Clinic

   ... monoclonal antibodies, other investigational agent) < 28 days prior to the first dose of study drug. Current or prior use of immunosuppressive medication ...

9. Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer - Mayo Clinic

   ... monoclonal antibody (mAb) targeting MET (such as onartuzumab [MetMAb]); The subject has received radionuclide treatment =< 6 weeks of the first dose of study ...

10. Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) - Mayo Clinic

    ... antibody (including ipilimumab, tremelimumab or any other antibody, or drug specifically targeting T cell co stimulatory or immune checkpoint pathways).